SLC6A4 and breast neoplasm: Our current efforts are centered on conditionally targeting SLC6A4 and the genes encoding TPH1 and each of the 14 5-HT receptors in human breast tumor cell lines to learn whether loss of each gene phenocopies the effect of selective serotonergic antagonists of their encoded molecular targets.